On April 20, Yingpai Pharmaceutical's IPO application on the Hong Kong Stock Exchange passed the hearing, meaning it is about to be listed.
Founded in 2009, Imbisoft is dedicated to advancing precision oncology therapies based on synthetic lethal mechanisms globally. Imbisoft has built a robust pipeline in the field of synthetic lethality, and is one of only three companies worldwide to simultaneously possess commercially viable PARP1/2 inhibitors and next-generation PARP1 inhibitors in clinical trials.

The pipeline for future research and development includes ATR inhibitors, WEE1 inhibitors, SHX9 inhibitors, brain-penetrating PARP1 inhibitors, ATM inhibitors, USP1 inhibitors, CHK1/2 inhibitors, and more.
Yingpai Pharmaceutical's R&D expenditures in 2024 and 2025 were RMB 195 million and RMB 184 million, respectively. As of the end of 2025, Yingpai Pharmaceutical had RMB 259 million in cash on hand.

In conclusion , regarding business development (BD) collaborations, Innovent Biologics licensed the overseas rights to its PARP1 inhibitors IMP1734 and IMP1707 to Eikon, which paid a $31.5 million upfront payment, $956 million in milestone payments, and a high single-digit to low double-digit percentage of sales revenue. Innovent Biologics also licensed the Chinese commercialization rights for its sennaparib to Sino-American East China Pharmaceutical Group, which paid a 100 million yuan upfront payment and 190 million yuan in milestone payments, with Innovent Biologics paying a percentage of sales service fees in return.

Yingpai Pharmaceuticals is also actively developing new technology platforms, including small molecules that utilize synthetic lethality mechanisms to develop dual-payload ADCs, as well as the PROTAC technology platform.

https://news.yaozh.com/archive/47861.html